Premium
Fluvoxamine (LUVOX™) use in pregnancy
Author(s) -
Sivojelezova A.
Publication year - 2004
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/j.clpt.2003.11.094
Subject(s) - fluvoxamine , medicine , pregnancy , depression (economics) , obstetrics , clinical pharmacology , serotonin reuptake inhibitor , birth weight , prospective cohort study , fluoxetine , pediatrics , antidepressant , serotonin , pharmacology , receptor , macroeconomics , biology , hippocampus , economics , genetics
Background Fluvoxamine is a selective serotonin reuptake inhibitor indicated for depression. Our primary goal is to investigate the safety of fluvoxamine in pregnancy. Methodology: this is a prospective, comparative study. Pregnant women, who contacted the Motherisk Program regarding the safety of fluvoxamine in pregnancy, were recruited. Their medical and obstetrical history was documented in a standardized in‐take form. A telephone follow‐up interview was conducted after the expected date of delivery. All exposed women were matched to a disease‐control group of women with depression and SSRI use in pregnancy. The second control group consisted of healthy pregnant women taking non‐teratogenic products. Matching criteria included age (±2 yrs), time of first call to Motherisk (±2 wks GA), and smoking/drinking habits. Results: 92 women were followed‐up (46 exposed and 46 disease‐matched women). Fetal survival rates, birth weight, and rates of major malformations did not differ statistically between both groups. In the fluvoxamine group we observed 2 (4.7%) major malformations, as compared to 2 (4.3%) malformations in the disease‐control group (P=0.52). Conclusion: this study is in progress, as we are planning to recruit more women in the non‐teratogenic group. Preliminary results suggest that the use of fluvoxamine during pregnancy does not appear to be associated with an increased risk of major malformations above the baseline risk of 1–5%. Clinical Pharmacology & Therapeutics (2004) 75 , P25–P25; doi: 10.1016/j.clpt.2003.11.094